Table of Contents
Abstract: When a Certificate of Analysis states “method validated per ICH Q2,” most procurement teams take it at face value. But what does validation actually prove—and what does it leave unsaid?
This guide decodes the seven validation parameters defined in ICH Q2(R2) from an intermediate buyer’s perspective, explains why stability-indicating methods matter for retest dating, and provides six questions buyers should ask suppliers about their analytical methods. We also cover what changed in the 2023 revision (Q2(R2)) and how it aligns with the ICH Q14 lifecycle approach. Every claim is referenced to the original guideline or pharmacopoeial standard.
You’ve seen it on hundreds of COAs: a column labeled “Method,” and next to it, something like “HPLC, validated per ICH Q2.” That single line is doing a lot of heavy lifting. It’s telling you that the numbers in the “Result” column are trustworthy—or at least, that they should be.
But here’s the problem. ICH Q2 doesn’t specify a single universal method. It defines what parameters a method must meet to be considered validated. A supplier can validate a method poorly and still truthfully write “validated per ICH Q2” on the COA. The validation might cover assay but not impurities. It might have an LOQ ten times above the reporting threshold. It might not be stability-indicating at all.
For intermediate buyers, understanding what’s behind that “validated” claim isn’t academic—it directly affects whether the material you receive will pass your own QC, whether your regulatory filing will hold up, and whether the retest date on the label means anything at all.
If you’re already familiar with reading COAs, this guide builds on our comprehensive COA reading guide by zooming in on the one column that most buyers gloss over: the Method column.
ICH Q2(R2) defines seven characteristics that must be evaluated when validating an analytical method. Not every parameter applies to every method type—assay methods need different validation than impurity methods, for instance—but understanding all seven helps you ask the right questions.
Specificity answers a simple question: can the method measure your target analyte without interference from anything else? In HPLC, that means the main peak must be cleanly separated from impurity peaks, degradation products, and excipients. If the method can’t distinguish your intermediate from a structurally similar impurity, every number on the COA becomes suspect.
How is specificity proven? Typically through forced degradation studies—subjecting the sample to acid (0.1M HCl), base (0.1M NaOH), peroxide (3% H₂O₂), heat (60°C), and light (1.2 million lux-hours) to generate degradation products, then confirming that these breakdown products don’t co-elute with the analyte peak. Peak purity analysis using photodiode array (PDA) detection or mass spectrometry provides additional confirmation.
ICH Q2(R2) also introduces a new concept: technology-inherent specificity. For techniques like mass spectrometry or NMR, the detection principle itself may provide adequate selectivity without additional experiments. This is a practical recognition that not every method needs the same level of demonstrated specificity.
Linearity means the method’s response is proportional to the concentration of the analyte across a defined range. In practice, you prepare at least five concentration levels and plot response versus concentration. The acceptance bar is a correlation coefficient (R²) of 0.999 or higher.
Why does this matter to buyers? If a method is linear only between 90% and 110% of the target concentration, it can’t reliably quantify an impurity present at 0.1%. The linearity range must cover the full span of concentrations the method is expected to measure.
Accuracy is the closeness of the measured value to the true value. It’s typically demonstrated through recovery studies: spiking a known amount of reference standard into the sample matrix and measuring how much you get back.
For assay methods, recovery should fall between 98.0% and 102.0%. For impurity methods, the acceptance range is wider—70% to 130% at the LOQ level, tightening to 80%–120% at higher concentrations. ICH Q2 calls for a minimum of nine determinations: three concentration levels (typically 80%, 100%, and 120% of target) with three replicates each.
Precision has three layers, and they all matter:
If a supplier’s method has great repeatability but poor intermediate precision, that means the method works fine under tightly controlled conditions but produces variable results in routine use. That’s a problem if you’re relying on the COA data for batch release decisions.
The range is the interval between the lowest and highest concentrations where the method provides acceptable accuracy, precision, and linearity. For assay, the typical range is 80%–120% of the target concentration. For impurity testing, it extends from the reporting threshold (typically 0.05% for related substances, per ICH Q3A) up to 120% of the specification limit.
These two parameters are where many COAs hide significant gaps:
For impurity testing on intermediates, the LOQ must be at or below the ICH Q3A reporting threshold of 0.05%. If a supplier’s method has an LOQ of 0.3%, they can truthfully report “no impurities detected above LOQ”—but they’d miss any impurity present between 0.05% and 0.3%. That’s a six-fold blind spot.
Robustness measures whether the method survives small, deliberate changes to its parameters: mobile phase pH (±0.2 units), organic modifier composition (±2%), column temperature (±5°C), flow rate (±10%), detection wavelength (±2 nm). It’s technically evaluated during method development rather than formal validation, but the results inform the system suitability criteria that appear on every COA.
A method with poor robustness means that minor variations in lab conditions—a different column batch, a slightly different room temperature—could shift the results. That’s exactly the kind of thing that causes batch-to-batch variability in COA data.
Here’s a scenario we see more often than we’d like: A buyer receives an intermediate with a 24-month retest date. The COA shows 99.5% purity. Six months later, they retest and find 94.2%. The supplier’s method wasn’t stability-indicating—it couldn’t detect the degradation products that formed during storage.
A stability-indicating method is one that can separate and quantify the analyte in the presence of its degradation products. Without it, the purity number on your COA is a snapshot that might not reflect what’s happening to the material over time.
How do you know if a method is stability-indicating? The validation report should include forced degradation data showing that degradation products are resolved from the main peak. If the supplier can’t provide this, the retest date on the label is essentially an unsubstantiated claim. For more on how retest dates work and what they mean for your inventory management, see our guide on intermediate retest date vs. expiry date.
This is one of the most overlooked aspects of method validation in intermediate procurement. ICH Q3A sets the reporting threshold for related substances in drug substances at 0.05% (for maximum daily dose ≤ 2g/day). But there’s no rule that says your supplier’s LOQ has to match that threshold.
Consider this real situation: A supplier validates an HPLC method for impurity testing with an LOQ of 0.15%. Their COA reports “no impurities above 0.15%.” A buyer accepts the material based on that COA. Later, during their own incoming QC testing with a method that has an LOQ of 0.03%, they find an unidentified impurity at 0.08%.
The supplier didn’t lie. They simply couldn’t see what your method could see. The gap between their LOQ and the reporting threshold is a blind spot—and until you ask, you won’t know how big it is.
When reviewing a COA, always check: Does the document state the LOQ for each impurity test? Is the LOQ at or below 0.05%? If not, “no impurities detected” means “no impurities detected above our LOQ”—which is a very different statement.
Switching intermediate suppliers isn’t just a procurement decision—it’s an analytical event. The method that worked perfectly on Supplier A’s material might behave differently on Supplier B’s, even if the chemical structure is identical. Different synthetic routes can produce different impurity profiles, different residual solvents, and different matrix effects.
ICH Q2(R2) addresses this through the concept of continued procedure verification—the third stage of the analytical lifecycle. When a method is transferred to a new lab or applied to material from a new source, you need to verify that it still performs adequately. This isn’t necessarily full revalidation, but it’s more than just running a few samples.
At minimum, method transfer between suppliers should include:
For a broader discussion of what switching suppliers triggers from a regulatory standpoint—including change classification and bridging studies—see our guide on ICH Q11 starting material selection.
Building on our general COA reading guide, here are five method-specific red flags that signal potential validation gaps:
ICH Q2 was originally published in 1994 and revised to R1 in 2005. The 2023 revision—Q2(R2)—represents the most significant update in nearly two decades. The key change is the integration of validation into the analytical procedure lifecycle described in ICH Q14 (Analytical Procedure Development).
Under the previous version, validation was a one-time event: you developed a method, validated it, and filed it. Q2(R2) introduces a three-stage lifecycle:
Other notable additions in Q2(R2) include guidance on multivariate analytical procedures (relevant for methods using chemometric models), technology-inherent specificity justification (as mentioned above), and expanded coverage of analytical techniques beyond traditional HPLC and GC—such as NMR, bioassays, and qPCR.
For intermediate buyers, the lifecycle approach means that “validated per ICH Q2(R2)” carries a stronger implicit promise than “validated per ICH Q2(R1)”: the supplier isn’t just checking boxes once; they’re committed to ongoing verification. Of course, the strength of that promise still depends on whether they actually follow through.
For a structured approach to evaluating all aspects of your supplier—not just their analytical methods—see our pharmaceutical intermediate supplier audit checklist. If your intermediate involves metal catalysts, our guide on elemental impurities per ICH Q3D covers what to look for in metals testing methods specifically.
What does “validated per ICH Q2” on a COA mean?
It means the analytical method used to test your intermediate has been proven reliable for its intended purpose through systematic evaluation of specificity, accuracy, precision, linearity, range, LOD, LOQ, and robustness as defined by ICH Q2(R2). However, the COA should specify which parameters were validated and at what limits—not just state “validated” generically.
What is the difference between LOD and LOQ in pharmaceutical testing?
LOD (Limit of Detection) is the lowest amount of an analyte that can be detected but not quantified, typically at a signal-to-noise ratio of 3:1. LOQ (Limit of Quantification) is the lowest amount that can be quantitatively measured with acceptable accuracy and precision, typically at a signal-to-noise ratio of 10:1. For impurity testing, the LOQ must be at or below the ICH reporting threshold of 0.05%.
What is a stability-indicating method and why does it matter for intermediates?
A stability-indicating method is an analytical procedure that can detect changes in the sample during storage—meaning it can separate the analyte from its degradation products. This matters because without a stability-indicating method, you cannot confidently set a retest date, because the method might not detect if the intermediate has degraded over time.
Do I need to revalidate analytical methods when switching intermediate suppliers?
It depends on whether the method is transferred intact or needs adaptation. If the same method works on the new supplier’s material without modification, method verification (not full revalidation) may suffice. However, if the new supplier’s material has a different matrix or impurity profile, the method may need partial or full revalidation to confirm specificity and accuracy.
How is ICH Q2(R2) different from the previous version?
ICH Q2(R2), adopted in 2023, integrates validation into the analytical lifecycle framework described in ICH Q14. Key changes include: multivariate analytical procedures, lifecycle management with continued verification, technology-inherent specificity justification for methods like mass spectrometry, and alignment with Q14’s enhanced approach to procedure development.
Switching intermediate suppliers for 20% lower price? Six hidden costs including bridging studies, regulatory filings, and method revalidation can reach $600K.
This guide decodes the seven validation parameters defined in ICH Q2(R2) from an intermediate buyer’s perspective, explains why stability-indicating methods matter for retest dating, and provides six questions buyers should ask suppliers about their analytical methods.
Learn how ICH Q11 starting material rules affect pharmaceutical intermediate sourcing—supplier boundaries, COA red flags, and a practical buyer’s checklist.
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.